Use of high molecular weight hyaluronic acid as ocular transporting vehicle

A method for delivering a bioactive agent into the eye, comprising topically co-administering high molecular weight hyaluronic acid (HMWHA) fluid and a bioactive agent to the ocular surface of a human or animal subject, wherein the hyaluronic acid has an intrinsic viscosity of at least 2.5 m3/kg, and wherein the HMWHA fluid transports the bioactive agent into the eye, wherein the bioactive agent is a nucleic acid, peptide, protein, antibody or antigen-binding fragment thereof, cyclosporine or ketotifen.

A method for treating, preventing, and/or delaying the onset or recurrence of an eye disorder in a human or animal subject, comprising topically co-administering high molecular weight hyaluronic acid (HMWHA) fluid and a bioactive agent to the ocular surface of a human or animal subject, wherein the hyaluronic acid has an intrinsic viscosity of at least 2.5 m3/kg, wherein the bioactive agent is capable of treating, preventing, or delaying the onset or recurrence of the eye disorder, and wherein the HMWHA fluid transports the bioactive agent into the eye, wherein the bioactive agent is a nucleic acid, peptide, protein, antibody or antigen-binding fragment thereof, cyclosporine, or ketotifen.